19249HAB9

Coherus Oncology, Inc.

Could not find a ticker for this position, may be a filing error

A biopharmaceutical company that develops and sells immuno-oncology medicines — therapies that help the immune system find and attack cancer cells. Its flagship product, LOQTORZI, is an FDA-approved treatment for nasopharyngeal carcinoma, a type of head and neck cancer. Founded in 2010 by a longtime Amgen executive, the company spent over a decade as a maker of lower-cost biosimilar drugs before selling those products and renaming itself Coherus Oncology in 2025 to focus purely on cancer treatments. The name "Coherus" evokes the word "cohere," reflecting the company's focus on combining different therapies to fight cancer.

CONVERTIBLEUnderlying: CHRSCUSIP: 19249HAB9HealthcareUS1 derivative reporter

1.500% Convertible Senior Subordinated Notes due 2026

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in all recorded history

Insider

Daiichi Sankyo Company, LTDFormer 10% Owner · 1 transaction

2.87M—

as of Nov 2014

KKR & Co. L.P. +9 co-filers10% owner · 1 transaction

2.50M—

as of Nov 2014

Lilly Eli & Co +1 co-filerFormer 10% Owner · 3 transactions

2.33M—

as of Nov 2014

Bought 165.0K

Troendle August J.Director · 17 transactions

1.94M—

as of Feb 2018

Granted 8.1K · Sold 590.0K

Lanfear Dennis MPresident & CEO, Director · 43 transactions

1.57M—

Granted 1.34M · Sold 1.15M

FMR LLCSee Remark 1 · 11 transactions

1.43M—

as of Aug 2016

Sold 148.6K

Healy JamesDirector · 23 transactions

504.6K—

as of Sep 2021

Granted 70.0K · Bought 425.9K · Sold 1.39M

Herman Alan C.Chief Scientific Officer · 49 transactions

350.6K—

as of Dec 2017

Granted 73.5K · Sold 237.7K

McMichael Bryan JChief Financial Officer · 8 transactions

133.7K—

Granted 125.0K

Anicetti Vincent RChief Operating Officer · 75 transactions

124.8K—

as of Jul 2021

Granted 374.4K · Sold 243.4K

Vexler VladimirChief Scientific Officer · 25 transactions

116.4K—

as of Mar 2023

Granted 337.1K · Sold 181.4K

Reider PaulChief Commercial Officer · 7 transactions

82.1K—

as of Jan 2025

Stilwell McDavidChief Financial Officer · 9 transactions

75.3K—

as of Dec 2023

Granted 100.0K · Bought 3.7K · Sold 3.5K

Richards ChristosDirector · 8 transactions

63.8K—

as of Jan 2019

Sold 15.0K

Viret Jean-FredericChief Financial Officer · 56 transactions

61.3K—

as of Feb 2021

Granted 206.1K · Sold 135.1K

Finck Barbara KChief Medical Officer · 13 transactions

37.0K—

as of Sep 2018

Granted 14.6K · Sold 7.0K

Szela Mary TDirector · 4 transactions

35.0K—

as of Jun 2020

Granted 55.0K · Sold 55.0K

Wahlstrom MatsDirector · 30 transactions

30.0K—

Granted 130.0K · Sold 602.6K

Karachun Rita ADirector · 1 transaction

30.0K—

Granted 30.0K

Newcomer Lee NisleyDirector · 1 transaction

30.0K—

Granted 30.0K

Newton Charles W.Director · 1 transaction

30.0K—

Granted 30.0K

O'Donnell-Tormey JillDirector · 1 transaction

30.0K—

Granted 30.0K

Ryan Michael LeeDirector · 1 transaction

30.0K—

Granted 30.0K

Satvat Ali J.Director · 1 transaction

30.0K—

Granted 30.0K

Watler Peter K.Chief Technical Officer · 20 transactions

5.9K—

as of Feb 2018

Granted 216.2K · Sold 210.3K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Daiichi Sankyo Company, LTDFormer 10% Owner · 1 transaction	—	2.87Mas of Nov 2014	—	—	—
KKR & Co. L.P. +9 co-filers10% owner · 1 transaction	—	2.50Mas of Nov 2014	—	—	—
Lilly Eli & Co +1 co-filerFormer 10% Owner · 3 transactions	—	2.33Mas of Nov 2014	—	165.0K	—
Troendle August J.Director · 17 transactions	—	1.94Mas of Feb 2018	8.1K	—	590.0K
Lanfear Dennis MPresident & CEO, Director · 43 transactions	—	1.57M	1.34M	—	1.15M
FMR LLCSee Remark 1 · 11 transactions	—	1.43Mas of Aug 2016	—	—	148.6K
Healy JamesDirector · 23 transactions	—	504.6Kas of Sep 2021	70.0K	425.9K	1.39M
Herman Alan C.Chief Scientific Officer · 49 transactions	—	350.6Kas of Dec 2017	73.5K	—	237.7K
McMichael Bryan JChief Financial Officer · 8 transactions	—	133.7K	125.0K	—	—
Anicetti Vincent RChief Operating Officer · 75 transactions	—	124.8Kas of Jul 2021	374.4K	—	243.4K
Vexler VladimirChief Scientific Officer · 25 transactions	—	116.4Kas of Mar 2023	337.1K	—	181.4K
Reider PaulChief Commercial Officer · 7 transactions	—	82.1Kas of Jan 2025	—	—	—
Stilwell McDavidChief Financial Officer · 9 transactions	—	75.3Kas of Dec 2023	100.0K	3.7K	3.5K
Richards ChristosDirector · 8 transactions	—	63.8Kas of Jan 2019	—	—	15.0K
Viret Jean-FredericChief Financial Officer · 56 transactions	—	61.3Kas of Feb 2021	206.1K	—	135.1K
Finck Barbara KChief Medical Officer · 13 transactions	—	37.0Kas of Sep 2018	14.6K	—	7.0K
Szela Mary TDirector · 4 transactions	—	35.0Kas of Jun 2020	55.0K	—	55.0K
Wahlstrom MatsDirector · 30 transactions	—	30.0K	130.0K	—	602.6K
Karachun Rita ADirector · 1 transaction	—	30.0K	30.0K	—	—
Newcomer Lee NisleyDirector · 1 transaction	—	30.0K	30.0K	—	—
Newton Charles W.Director · 1 transaction	—	30.0K	30.0K	—	—
O'Donnell-Tormey JillDirector · 1 transaction	—	30.0K	30.0K	—	—
Ryan Michael LeeDirector · 1 transaction	—	30.0K	30.0K	—	—
Satvat Ali J.Director · 1 transaction	—	30.0K	30.0K	—	—
Watler Peter K.Chief Technical Officer · 20 transactions	—	5.9Kas of Feb 2018	216.2K	—	210.3K

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.